Transcription of Management of Multidrug-Resistant Organisms In …
{{id}} {{{paragraph}}}
Example: bankruptcy
Management of Multidrug-Resistant Organisms In …
Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006 Available from: 1 of 74 Last update: February 15, 2017 Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006 Jane D. Siegel, MD; Emily Rhinehart, RN MPH CIC; Marguerite Jackson, PhD; Linda Chiarello, RN MS; the Healthcare Infection Control Practices Advisory Committee Acknowledgement: The authors and HICPAC gratefully acknowledge Dr. Larry Strausbaugh for his many contributions and valued guidance in the preparation of this guideline. Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006 Available from: 2 of 74 Last update: February 15, 2017 Healthcare Infection Control Practices Advisory Committee (HICPAC): Chair Patrick J. Brennan, MD Professor of Medicine Division of Infectious Diseases University of Pennsylvania Medical School Executive Secretary Michael Bell, MD Division of Healthcare Quality Promotion National Center for Infectious Diseases Centers for Disease Control and Prevention Members BRINSKO, Vicki L.
Feb 15, 2017 · Multidrug-resistant organisms (MDROs), including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and certain gram-negative bacilli (GNB) have important infection control implications that either have not been addressed or received only limited consideration in previous isolation guidelines.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: